Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 65

Sort by

Sort Order Select

Journal Articles

Allogeneic Stem Cell Transplantation for Relapsed and/or Refractory Hodgkin Lymphoma: A Multicenter Real World Experience

Derya Koyun, Uğur Şahin, Güldane Cengiz Seval, Deniz Gören Şahin, Ayla Gökmen, Sinem Civriz Bozdağ, Selami Kocak Toprak, Pervin Topçuoğlu, Meltem Kurt Yüksel, Önder Arslan, Taner Demirer, Günhan Gürman, Osman İlhan, Meral Beksac, Muhit Özcan, Mutlu Arat

Blood (2023) 142 (Supplement 1): 3617.

https://doi.org/10.1182/blood-2023-182741

Published: 2023

Journal Articles

Single Center Real World Data That Compares Autologous Stem Cell Transplant in the Era of Anti-CD38 Monoclonal Antibody Based Treatments for AL Amyloidosis

Hulya Yilmaz, Guldane Cengiz, Bulent Karakaya, Gul Yavuz, Merve Aydogan, Sinem Civriz Bozdag, Selami Kocak Toprak, Meltem Kurt Yuksel, Pervin Topçuoğlu, Onder Arslan, Muhit Ozcan, Osman Ilhan, Meral Beksac

Blood (2022) 140 (Supplement 1): 4369–4370.

https://doi.org/10.1182/blood-2022-170132

Published: 2022

Journal Articles

The Impact of CD34+ Cell and Immunefector Cell Dose on Transplant Outcomes

Derya Koyun, Guldane Cengiz, Sinem Civriz Bozdag, Selami Kocak Toprak, Pervin Topçuoğlu, Muhit Özcan, Onder Arslan, Taner Demirer, Osman İlhan, Gunhan Gurman, Meral Beksac, Meltem Kurt Yuksel

Blood (2022) 140 (Supplement 1): 12673–12674.

https://doi.org/10.1182/blood-2022-155998

Published: 2022

Journal Articles

Neutrophil and platelet increases with luspatercept in lower-risk MDS: secondary endpoints from the MEDALIST trial

Guillermo Garcia-Manero, Ghulam J. Mufti, Pierre Fenaux, Rena Buckstein, Valeria Santini, María Díez-Campelo, Carlo Finelli, Osman Ilhan, Mikkael A. Sekeres, Amer M. Zeidan, Rodrigo Ito, Jennie Zhang, Anita Rampersad, Daniel Sinsimer, Jay T. Backstrom, Uwe Platzbecker, Rami S. Komrokji

Blood (2022) 139 (4): 624–629.

https://doi.org/10.1182/blood.2021012589

Published: 2022

Journal Articles

The Outcome of Autologous Hematopoietic Cell Transplantation in Elderly Patients with Aggressive Non-Hodgkin Lymphoma

Osman Ilhan, Guldane Cengiz Seval, Sinem Civriz Bozdag, Selami Kocak Toprak, Meltem Kurt Yuksel, Pervin Topcuoglu, Onder Arslan, Muhit Özcan, Taner Demirer, Gunhan Gurman, Meral Beksac

Blood (2021) 138 (Supplement 1): 4906.

https://doi.org/10.1182/blood-2021-153905

Published: 2021

Journal Articles

Post-Induction Undetectable Minimal Residual Disease at 10 -5 Sensitivity Level within Marrow and/or Stem Cell Graft Overrides Cytogenetic High Risk

Guldane Cengiz Seval, Klara Dalva, Dilek Oz, Sule Mine Bakanay, Ender Soydan, Gunhan Gurman, Osman Ilhan, Meral Beksac

Blood (2021) 138 (Supplement 1): 2909.

https://doi.org/10.1182/blood-2021-148879

Published: 2021

Journal Articles

Ibrutinib As a Promising Treatment for Heavily Pretreated Waldenström Macroglobulinemia: A Real World Data

Osman Ilhan, Guldane Cengiz Seval, Ferit Avcu, MD, Burhan Ferhanoglu, MD, Güven Çetin, Erdal Kurtoglu, Figen Atalay, MD, Emine Gulturk, Meliha Nalcaci, Meral Beksac, MD

Blood (2020) 136 (Supplement 1): 14–15.

https://doi.org/10.1182/blood-2020-138899

Published: 2020

Journal Articles

Evaluation of Patients with PNH Treated By Eculizumab: Real World Data from Turkey

Blood (2019) 134 (Supplement_1): 4805.

https://doi.org/10.1182/blood-2019-128743

Published: 2019

Journal Articles

Large Granular Lymphocytosis and Its Impact on Long Term Clinical Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation: 14-Year Follow-up Data

Guldane Cengiz Seval, Atilla Uslu, MD, Ekin Kircali, Sinem Civriz Bozdag, MD, Klara Dalva, MD, Selami Kocak Toprak, MD, Meltem Kurt Yuksel, MD, Pervin Topcuoglu, MD, Isinsu Kuzu, Onder Arslan, Muhit Özcan, Taner Demirer, MD, Osman Ilhan, MD, Hamdi Akan, MD, Meral Beksac, MD, Gunhan Gurman, MD

Blood (2019) 134 (Supplement_1): 2019.

https://doi.org/10.1182/blood-2019-128750

Published: 2019

Journal Articles

Obinutuzumab Alone or Combined with Chemotherapy in Previously Untreated (Fit or Unfit) or Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Patients: Final Results from the Phase IIIb GREEN Safety Study with a Focus on Efficacy

Stephan Stilgenbauer, MD, Francesc Bosch, MD PhD, Véronique Leblond, MD PhD, Osman Ilhan, MD, Jens Kisro, Béatrice Mahé, MD, Eva Mikuskova, MD PhD, Dzhelil Osmanov, MD, Gianluigi Reda, MD, Eugen Tausch, Marcin Wójtowicz, MD PhD, Thomas Perretti, MD MSc, Marlies EHM Van Hoef, MD PhD MBA, Robin Foà, MD

Blood (2019) 134 (Supplement_1): 3035.

https://doi.org/10.1182/blood-2019-123419

Published: 2019

Journal Articles

Effect of Cyclophosphamide on Hemorrhagic Cystitis Following Haploidentical Related Compared to Matched Related/Unrelated Donor Hematopoietic Stem Cell Transplantation: A 7-Year Tertiary Center Analysis

Guldane Cengiz Seval, Nergis Ozturk, Sinem Civriz Bozdag, MD, Meltem Kurt Yuksel, MD, Pervin Topcuoglu, MD, Onder Arslan, Muhit Özcan, Taner Demirer, MD, Gunhan Gurman, MD, Osman Ilhan, Hamdi Akan, MD, Meral Beksac, MD, Selami Kocak Toprak, MD

Blood (2019) 134 (Supplement_1): 4504.

https://doi.org/10.1182/blood-2019-127651

Published: 2019

Journal Articles

Hematologic Improvement-Neutrophil and -Platelet in the MEDALIST Trial: Multilineage Data from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept to Treat Anemia in Patients with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions

Guillermo Garcia-Manero, MD, Ghulam J. Mufti, Pierre Fenaux, MD PhD, Rena Buckstein, MD FRCPC, Valeria Santini, MD, María Díez-Campelo, MD PhD, Carlo Finelli, Mario Cazzola, MD, Osman Ilhan, Mikkael A. Sekeres, MD MS, Alan F. List, MD, Abderrahmane Laadem, Rodrigo Ito, Jennie Zhang, Anita Rampersad, Daniel Sinsimer, Peter G. Linde, Uwe Platzbecker, MD, Rami Komrokji

Blood (2019) 134 (Supplement_1): 4243.

https://doi.org/10.1182/blood-2019-123048

Published: 2019

Journal Articles

Which One, Generic Vs Original Glivec Is More Effective in Patients with Chronic Myeloid Leukemia?

Ekin Kircali, Guldane Cengiz Seval, Sinem Civriz Bozdag, MD, Selami Kocak Toprak, MD, Meltem Kurt Yuksel, MD, Onder Arslan, Muhit Özcan, Taner Demirer, MD, Gunhan Gurman, MD, Osman Ilhan, Hamdi Akan, MD, Meral Beksac, MD, Pervin Topcuoglu, MD

Blood (2019) 134 (Supplement_1): 4156.

https://doi.org/10.1182/blood-2019-127622

Published: 2019

Journal Articles

Assessment of Longer-Term Efficacy and Safety in the Phase 3, Randomized, Double-Blind, Placebo-Controlled MEDALIST Trial of Luspatercept to Treat Anemia in Patients (Pts) with Revised International Prognostic Scoring System (IPSS-R) Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions

Blood (2019) 134 (Supplement_1): 841.

https://doi.org/10.1182/blood-2019-123064

Published: 2019

Journal Articles

Impact of ABO Mismatch on Outcomes of Allogeneic Hematopoietic Stem Cell Recipients: 30 Years of Experience with 1016 Patients

Erden Atilla, MD, Pervin Topcuoglu, MD, Erman Akkus, MD, Pinar Ataca Atilla, MD, Sinem Civriz Bozdag, MD, Meltem Kurt Yuksel, MD, Taner Demirer, MD, Muhit Özcan, Meral Beksac, MD, Osman Ilhan, MD, Hamdi Akan, MD, Onder Arslan, MD, Gunhan Gurman, MD, Selami Kocak Toprak, MD

Blood (2018) 132 (Supplement 1): 3472.

https://doi.org/10.1182/blood-2018-99-118314

Published: 2018

Journal Articles

Residual Clonal Plasma Cells Detected By Flow Cytometry at 10 -4 level within Autologous Stem Cell Grafts Is Associated with Significantly Less Overall Survival

Guldane Cengiz Seval, Klara Dalva, MD, Sule Mine Bakanay, Mustafa Merter, MD, Ugur Sahin, MD, Atilla Uslu, MD, Cemaleddin Ozturk, Osman Ilhan, MD, Meral Beksac, MD

Blood (2018) 132 (Supplement 1): 3438.

https://doi.org/10.1182/blood-2018-99-111794

Published: 2018

Journal Articles

Retrospective Analysis of 149 Unselected Patients with Mantle Cell Lymphoma Confirms Prognostic Relevance of Mantle Cell Lymphoma International Prognostic Index: Single Center Experience

Guldane Cengiz Seval, Bahar Ulas, Onur Tascı, Fulya Ozel, MD, Buğu Bulat, Isinsu Kuzu, Sinem Civriz Bozdag, MD, Selami Kocak Toprak, MD, Meltem Kurt Yuksel, MD, Pervin Topcuoglu, MD, Muhit Özcan, Meral Beksac, MD, Osman Ilhan, MD, Gunhan Gurman, Onder Arslan

Blood (2018) 132 (Supplement 1): 5331.

https://doi.org/10.1182/blood-2018-99-120370

Published: 2018

Journal Articles

Donor Lymphocyte Infusions for Relapsed Hematological Malignancies after Allogeneic Hematopoietic Stem Cell Transplantation: Single Center Experience

Gunhan Gurman, MD, Guldane Cengiz Seval, Sinem Civriz Bozdag, MD, Selami Kocak Toprak, MD, Meltem Kurt Yuksel, MD, Pervin Topcuoglu, MD, Onder Arslan, MD, Muhit Özcan, Taner Demirer, MD, Osman Ilhan, MD, Meral Beksac, MD, Hamdi Akan, MD

Blood (2018) 132 (Supplement 1): 4673.

https://doi.org/10.1182/blood-2018-99-120202

Published: 2018

Journal Articles

The Medalist Trial: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept to Treat Anemia in Patients with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions

Blood (2018) 132 (Supplement 1): 1.

https://doi.org/10.1182/blood-2018-99-110805

Published: 2018

Journal Articles

Evaluation of Elderly Patients with Hematological Malignancies By Two Different Geriatric Risk Scoring Systems: G8 and Flemish Version of the Triage Risk Screening Tool (fTRST)

Erden Atilla, MD, Merih Yalciner, MD, Ozlem Kilic, RN, Nurhayat Muftuoglu, RN, Pinar Ataca Atilla, MD, Sinem Civriz Bozdag, MD, Selami Kocak Toprak, MD, Meltem Kurt Yuksel, MD, Muhit Özcan, Gunhan Gurman, MD, Osman Ilhan, MD

Blood (2018) 132 (Supplement 1): 5902.

https://doi.org/10.1182/blood-2018-99-118275

Published: 2018

NARROW

Allogeneic Stem Cell Transplantation for Relapsed and/or Refractory Hodgkin Lymphoma: A Multicenter Real World Experience

Single Center Real World Data That Compares Autologous Stem Cell Transplant in the Era of Anti-CD38 Monoclonal Antibody Based Treatments for AL Amyloidosis

The Impact of CD34+ Cell and Immunefector Cell Dose on Transplant Outcomes

Neutrophil and platelet increases with luspatercept in lower-risk MDS: secondary endpoints from the MEDALIST trial

The Outcome of Autologous Hematopoietic Cell Transplantation in Elderly Patients with Aggressive Non-Hodgkin Lymphoma

Post-Induction Undetectable Minimal Residual Disease at 10 -5 Sensitivity Level within Marrow and/or Stem Cell Graft Overrides Cytogenetic High Risk

Ibrutinib As a Promising Treatment for Heavily Pretreated Waldenström Macroglobulinemia: A Real World Data

Evaluation of Patients with PNH Treated By Eculizumab: Real World Data from Turkey

Large Granular Lymphocytosis and Its Impact on Long Term Clinical Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation: 14-Year Follow-up Data

Obinutuzumab Alone or Combined with Chemotherapy in Previously Untreated (Fit or Unfit) or Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Patients: Final Results from the Phase IIIb GREEN Safety Study with a Focus on Efficacy

Effect of Cyclophosphamide on Hemorrhagic Cystitis Following Haploidentical Related Compared to Matched Related/Unrelated Donor Hematopoietic Stem Cell Transplantation: A 7-Year Tertiary Center Analysis

Which One, Generic Vs Original Glivec Is More Effective in Patients with Chronic Myeloid Leukemia?

Impact of ABO Mismatch on Outcomes of Allogeneic Hematopoietic Stem Cell Recipients: 30 Years of Experience with 1016 Patients

Residual Clonal Plasma Cells Detected By Flow Cytometry at 10 -4 level within Autologous Stem Cell Grafts Is Associated with Significantly Less Overall Survival

Retrospective Analysis of 149 Unselected Patients with Mantle Cell Lymphoma Confirms Prognostic Relevance of Mantle Cell Lymphoma International Prognostic Index: Single Center Experience

Donor Lymphocyte Infusions for Relapsed Hematological Malignancies after Allogeneic Hematopoietic Stem Cell Transplantation: Single Center Experience

The Medalist Trial: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept to Treat Anemia in Patients with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions

Evaluation of Elderly Patients with Hematological Malignancies By Two Different Geriatric Risk Scoring Systems: G8 and Flemish Version of the Triage Risk Screening Tool (fTRST)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only